MedTech Innovator Vantage Non-Dilutive Funding Program: Up to $200K for Health Security Diagnostics and Devices

MedTech Innovator Vantage is a joint partnership between MedTech Innovator and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. Vantage is one of five specialized hubs in the BARDA Accelerator Network. Its Non-Dilutive Funding Program awards $50,000 to $200,000 for six-month, milestone-based projects that develop, evaluate, and validate diagnostic and medical device technologies for health security, preparedness, and response.

Deadline: Proposals are due October 15, 2026. Off-cycle applications for BARDA-aligned technologies are also accepted on a rolling basis.

Why This Opportunity Matters

Most early-stage medtech companies chase SBIR as their first federal dollar. Vantage is a faster, smaller entry point. A $50K to $200K award gives a startup proof-of-concept or validation data, a BARDA-aligned project record, and six months of project management and mentoring from subject matter experts. That record strengthens a later BARDA BAA, DRIVe, or SBIR application.

Key Facts at a Glance

• Sponsors: MedTech Innovator and BARDA (HHS), through the BARDA Accelerator Network
• Award size: $50,000 to $200,000
• Project length: 6 months, milestone-based
• Who can apply: Early-stage startups and university-backed projects
• Proposal window: September 1 to October 15, 2026
• Guided revisions: January 2027, with subject matter experts
• Award announcements: Anticipated March to April 2027
• Support included: Project management support and regular expert mentoring during the award
• Contact: vantage@medtechinnovator.org

Priority Technology Areas

Vantage funds diagnostic and medical device technologies that strengthen U.S. health security. Current priority areas include:

• Continuous patient monitoring: Platforms with advanced sensors, with emphasis on radiation injury and acute radiation syndrome
• Multiplexed point-of-care rapid tests: High-sensitivity tests, including botulinum toxin detection that distinguishes serotypes
• Deployable diagnostics: Low-cost tools for resource-limited settings
• Rapid triage diagnostics: Including low-throughput next-generation sequencing platforms for pathogen identification

What Is Out of Scope

• Oncology and chronic disease research
• Gain-of-function research involving pathogen manipulation

Is Your Company a Fit?

Vantage is a strong fit if your company:

• Is an early-stage startup or a university-backed spinout
• Is building a diagnostic, patient monitoring, or medical device technology with a clear health security use case
• Can define concrete, measurable milestones achievable in six months
• Plans to pursue larger BARDA or other federal funding after proof-of-concept

If your device targets cancer or a chronic disease without a preparedness or emergency response angle, other programs such as NIH SBIR are a better match.

How to Apply

1. Confirm alignment. Review BARDA's mission and the DRIVe target product profiles to map your technology to a stated health security need.
2. Define six-month milestones. Reviewers fund projects with specific development, evaluation, or validation outcomes that a $50K to $200K budget can deliver.
3. Submit by October 15, 2026. Proposals go to MedTech Innovator during the September 1 to October 15 window.
4. Revise with experts. Selected applicants refine proposals with subject matter experts in January 2027.
5. Award decision. Announcements are expected March to April 2027.

How BW&CO Helps

BW&CO has helped deep-tech, medtech, and biotech founders secure $350M+ in non-dilutive funding. We help you test fit against BARDA priorities, frame milestones reviewers trust, and plan the path from a Vantage award to BARDA BAA, DRIVe, and SBIR funding.

Frequently Asked Questions

What is the MedTech Innovator Vantage Non-Dilutive Funding Program?

It is a BARDA-aligned funding program run by MedTech Innovator that awards $50,000 to $200,000 for six-month projects developing, evaluating, and validating diagnostic and medical device technologies for health security.

When is the Vantage application deadline?

The 2026 proposal window runs September 1 to October 15, 2026. Off-cycle applications for BARDA-aligned technologies are accepted on a rolling basis.

Who is eligible to apply?

Early-stage startups and university-backed projects developing diagnostic or medical device technologies aligned with BARDA's health security mission.

Is Vantage funding dilutive?

No. Vantage awards are non-dilutive, so companies do not give up equity.

What technologies does Vantage prioritize?

Continuous patient monitoring for radiation injury, multiplexed point-of-care rapid tests such as botulinum toxin detection, low-cost deployable diagnostics, and rapid triage diagnostics including low-throughput NGS pathogen identification.

What is excluded from Vantage funding?

Oncology and chronic disease research, and gain-of-function research involving pathogen manipulation.

When are Vantage awards announced?

Selected applicants complete guided revisions in January 2027, and awards are anticipated in March to April 2027.